Developing orphan drugs involves navigating intricate regulatory landscapes, financial risks, and limited clinical data. To ...

Mergers and acquisitions (M&As) in the biopharmaceutical industry surged 101% in total deal value in the first quarter (Q1) ...

The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.

Bristol Myers Squibb (BMS) plans to invest $40bn in the US over the next five years to bolster its research and manufacturing ...

Research and development (R&D) investment in the Swiss biotech sector grew in 2024, despite ongoing global funding struggles.

Recursion Pharmaceuticals has narrowed its drug development pipeline as it seeks to reduce costs and reprioritise resources.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), once focused on treating diabetes and obesity, are now emerging as ...

The options are for the freeze-dried version of Bavarian Nordic’s Jynneos, a formulation that allows easier stockpiling.

The US FDA has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg oral formulation of Wegovy ...

TAE Life Sciences (TLS) has signed a letter of intent with the OSUCCC – James to develop boron-based drug compounds for ...

China NMPA's Center for Drug Evaluation (CDE) has granted priority review for InnoCare Pharma's zurletrectinib (ICP-723) ...